Go Beyond the Tumor
Breakthrough research from Teiko scientists and others shows that Immunotherapies act on the immune system outside the tumor. This action is now measurable in peripheral blood through the TokuProfile.
Understanding how a therapy works at a cellular level can improve trial design and accelerate candidates to approval.
No current immunotherapy biomarkers use information about the immune system outside the tumor.
Immune system outside tumor microenvironment is required for response
Cell publication has shown that when mice treated with a checkpoint inhibitor AND an agent that trapped immune cells in the secondary tissues, the tumor grew. This is a surprising conclusion. Traditionally, scientists believed that the checkpoint inhibitor worked directly on the tumor.
UNTREATED
The immune system fights the tumor but is unable to keep the tumor from growing.
TREATED
When treated with a checkpoint inhibitor, the tumor shrinks. But were immune cells in the blood outside the tumor even needed?
TREATED, BUT…
Yes! Researchers paired the original treatment with another drug which traps immune cells in the lymph nodes.
Accelerate the Pipeline
- Discovery Mechanism of action
Mechanism of resistance
Rational combinations - Phase I/II ID response characteristics
Novel pathway identification
Rational combinations - Phase III Likelihood for Response
Likelihood for Adverse Events
Novel Pathway Identification
A TokuProfile™ Can Reveal Unique Insights
Before Teiko.bio
The assumption is that CD8 T-cells need to be targeted directly. However, this leads to therapy failure.
With Teiko.bio
Profiling reveals that even though CD8 T-cells appear suppressed, the actual issue is with the Dendritic Cells not being active.
After Teko.bio
Anti CD40 Therapy Activates Dendritic Cells to create therapy success.
